FDA won't reorganize medical product centers, Makary says in interview: 'I rejected that proposal'

Zachary Brennan

Senior Editor

The FDA plans to consolidate some administrative functions, but won’t embark on a wholesale reorganization of the review centers that oversee drugs, biologics and medical …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

FDA won't reorganize medical product centers, Makary says in interview: 'I rejected that proposal'

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Uro-Oncology Business Manager

ImmunityBio, Inc.

Remote

FDA delays PDUFA date for small biotech, raising questions about impact of agency cuts

Pfizer CEO Bourla suggests pharma tariffs will focus on US adversaries, not allies

Pfizer launches a new wave of cost cuts, expects $7.7B in total savings through 2027

FDA approves Abeona’s skin disease cell therapy

Artios drug exploits ‘replication stress’ in cancer, shrinking subset of tumors in early study

Revolutionizing obesity treatment: Could mitochondria hold the key to unlocking fat-specific weight loss?

FDA won't re­or­ga­nize med­ical prod­uct cen­ters, Makary says in in­ter­view: 'I re­ject­ed that pro­pos­al'

Senior Editor

Sign up to read this article for free.

ImmunityBio, Inc.

Remote

FDA won't reorganize medical product centers, Makary says in interview: 'I rejected that proposal'